142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
415 432 9270
https://www.89bio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 70
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Rohan Palekar | CEO & Director | 1.06M | 無 | 1966 |
Dr. Harry Mansbach M.D. | Chief Medical Officer | 732.87k | 無 | 1965 |
Mr. Ryan Stephen Martins | Chief Financial Officer | 無 | 無 | 1979 |
Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | 無 | 無 | 1966 |
Ms. Annie J. Chang M.B.A. | VP of Investor Relations & Corporate Communications | 無 | 無 | 無 |
Ms. Amanda Kurihara | Vice President of People & Culture | 無 | 無 | 無 |
Ms. Yun Bai Ph.D. | VP and Head of Chemistry, Manufacturing & Controls ( CMC ) | 無 | 無 | 無 |
Ms. Melissa Abel | Senior Vice President of Commercial Strategy | 無 | 無 | 無 |
Mr. Paul Shin | Senior Vice President of R&D Operations | 無 | 無 | 無 |
Mr. Michael Baldwin | VP & Head of Quality | 無 | 無 | 無 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
截至 2024年5月1日 止,89bio, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:7;董事會:7;股東權利:9;現金賠償:8。